Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)		3 Months Ended
		Jun. 30, 2018	Jun. 30, 2017
Income Statement
Revenue		$ 17,660
Expenses:
General and administrative expenses	[1]	2,128,305	1,066,659
Research and development expenses		309,871	315,110
Total Operating Expenses		2,438,176	1,381,769
Accretion expense	[2]		879,416
Change in fair value of derivative liabilities	[3]		42,128
Net loss before income taxes		(2,420,516)	(2,303,313)
Income taxes
Net loss		(2,420,516)	(2,303,313)
Translation adjustment		(102,649)	(86,490)
Comprehensive loss		$ (2,523,165)	$ (2,389,803)
Loss per share, basic and diluted		$ (0.076)	$ (0.084)
Weighted average number of common shares outstanding		31,945,349	27,512,483

[1] See Notes 7, 8 and 9

[2] See Note 5

[3] See Note 6